Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18253238 | 0.95 | POLB (0.52) | GAAMAPTCASP3CASP7SMN1; SMN2 | |
| SCHEMBL25168128 | 0.90 | GAA (0.60) | GAAMAPTCASP3CASP7SMN1; SMN2 | |
| SCHEMBL20302878 | 0.81 | GAA (0.66) | GAAMAPTSMN1; SMN2ALDH1A1POLB | |
| 2-Chloro-3-Morpholino-1,4-Naphthoquinone SCHEMBL29590404 | 0.78 | NSD2 (0.67) | GAAMAPTCASP3SMN1; SMN2ALDH1A1 | |
| 2-Chloro-3-Morpholino-1,4-Naphthoquinone SCHEMBL197256 | 0.78 | NSD2 (0.67) | GAAMAPTCASP3SMN1; SMN2ALDH1A1 | |
| SCHEMBL21467803 | 0.71 | RAD51 (0.53) | MAPTSMN1; SMN2ALDH1A1POLBTSHR | |
| SCHEMBL12793245 | 0.71 | POLB (0.88) | GAASMN1; SMN2ALDH1A1POLBKDM4E | |
| SCHEMBL5307467 | 0.70 | POLB (0.73) | GAAMAPTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL16735251 | 0.70 | LMNA (0.62) | GAAMAPTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1459692 | 0.70 | SMN1; SMN2 (0.71) | GAAMAPTSMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160339036-A1 | Compound with Anti-Cancer Properties | VELGENE 3 LIMITED (HU) | 2016-11-24 | — | — | US | disclosed |
| US-20160339036-A1 | Compound with Anti-Cancer Properties | VELGENE 3 LIMITED (HU) | 2016-11-24 | — | — | US | disclosed |
| WO-2015079068-A1 | COMPOUND WITH ANTI-CANCER PROPERTIES | VELGENE 3 LIMITED (HU) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339036-A1 | Compound with Anti-Cancer Properties | ATG7, BECN1, SQSTM1 | GAA 336/4885MAPT 316/4885CASP3 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.